Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
dDAVP test for urinary concentrating defects in lithium-treated patients
2012-001809-24Phase 4Active
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of desmopressin in Nephrogenic Diabetes Insipidus (NDI) and lithium toxicity, sponsored by Radboud University Medical Center. Primary endpoint: Maximal renal concentrating ability. Started Sep 2012; status: active.
02
Drugs
desmopressin
03
Conditions
Nephrogenic Diabetes Insipidus (NDI)lithium toxicity
Beyond the preview
Go deeper on 2012-001809-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001809-24.